46 results about "Early hcc" patented technology

The technical scheme of the invention provides a gene chip for predicting liver cancer metastasis and recurrence risk, which comprises a substrate and a probe arranged on the substrate, wherein the probe consists of 149 genes. The gene chip for predicting the liver cancer metastasis and the recurrence risk has the advantages that: due to the adoption of genome comparison research, a large sample independently proves that a prediction model can accurately predict and evaluate the metastasis potential of liver cancer patients. Therefore, postoperative survival and metastasis, and recurrence of the patient can be accurately predicted (even early liver cancer patients can be accurately predicted). The gene chip contributes to early identifying or predicting high-risk patients so as to perform intensive monitoring and effective intervention on the high-risk patients to further prolong the life of the tumor patients.

The invention relates to a marker for intestinal microecology and application thereof, in particular to a biomarker used for early diagnoses of liver cancer. The biomarker used for early diagnoses ofliver cancer is composed of 34 kinds of genes shown as SEQ ID NO:1-34, and the genes are enriched in intestinal tracts. The invention also provides a detection reagent, and the reagent includes a primer used for detecting the 34 kinds of genes shown as SEQ ID NO:1-34. Feces of patients in groups are collected through a noninvasive method, and 16S rRNA Miseq sequencing of intestinal florae is conducted. During a discovery period of the biomarker, through a random forest law, microorganism gene markers with specificity of early liver cancer are identified among patients suffering from early cirrhosis and liver cancer, patients suffering from cirrhosis and healthy comparisons, an index of a probability of disease (POD) of liver cancer is created, and verification of the markers during the discovery period is achieved. During the verification period of the markers, the POD index of the patients during the verification period is calculated, and verification of the diagnosis value of the patients suffering from liver cancer during the verification period according to the POD index is achieved.

The invention belongs to the field of molecular biology (tumor screening), particularly relates to a technology for carrying out early warning and screening on liver tumor, and aims to solve the technical problem to provide a new choice for early prediction of the liver tumor. The technical scheme of the invention is that a kit for carrying out early warning and screening on liver tumor comprises a primer which is used for amplifying the following genes of an RASSF1A (Ras-association Domain Family 1A) gene of which a promoter is in a CpG island methylation state, a p16 gene, ELF (Embryonic Liver Fodrin), an SOCS (Suppressors of Cytokine Signaling)-3 gene, an SFRP1 (Secreted Frizzled-Related Protein 1) gene and a genome repetitive sequence LINE1 (Long Interspersed Nuclear Elements 1). According to the kit disclosed by the invention, a new effective inspection method is provided for carrying out early warning and screening on early liver tumor and liver cirrhosis; the cost is low, the use is very convenient, the flexibility is high, the specificity is good, and the application prospect is very good.

The invention belongs to the fields of biotechnology and medicine, and particularly relates to application of plasma exosome miR-455-3p as an early liver cancer diagnostic marker.

The invention discloses a transcriptome-sequencing-based gene group for early diagnosis of liver cancer and prognostic evaluation and application thereof; the gene group comprises four genes, GPC3, HSP70, GS and PIVKA-II. Recurrence risk value is calculated according to expression amounts of the four genes, whether a patient under test carries early liver cancer or not and prognostic recurrence rate of a patient with liver cancer are judged according to the recurrence risk value. An algorithm to calculate the recurrence risk value via the expression amounts is RS=0.080*GP3+0.098*HSP70+0.047*GS+0.13*PIVKA-II. Preclinical verification results are precise, diagnostic sensitivity for early primary liver cancer reaches 100%, and diagnostic sensitivity for non-liver cancers reaches 100%, prediction sensitivity to a low-recurring risk patient reaches 100%, prediction sensitivity to a medium-recurring risk patient reaches 96.774%, prediction sensitivity to a high-recurring risk patient reaches 99.375%, and detection capacity and efficiency are improved with detection cost greatly reduced; clear tips can be provided upon a patient's prognosis.

The invention discloses an application of microRNA-miR-3126-5p in serum serving as a diagnostic marker of liver cancer. In the invention, a high-throughput chip is used for detecting expression of microRNA in liver cancer cells at different development stages and in clinical liver cancer serum samples, candidate microRNA is selected, the expression of the candidate microRNA in the serum samples is detected to find that the miR-3126-5p has good sensitivity and specificity on diagnosis of liver cancer and especially has a good diagnostic value in diagnosis of early liver cancer and liver cancer with low AFP expression. On the basis, the invention develops a primer, a kit and a detection method for detecting the miR-3126-5p, which have good development prospects and clinical application values. The sequence of the primer is as shown in SEQ ID NO.2, and the kit is composed of a microRNA extraction reagent, a reverse transcription reagent, a specific amplification primer and a PCR amplification reagent.

The invention relates to a miRNA composition and a kit thereof for diagnosis of early hepatocellular carcinoma. The method discloses a method for the diagnosis of hepatocellular carcinoma, and in particular early hepatocellular carcinoma, through cooperative detection of expression of five miRNAs for the first time; and the invention also provides a reagent for implementing the diagnosis.

The invention discloses an application of miR-107 combined with miR-1246 as an early diagnostic marker for hepatocellular carcinoma metastasis. Researches find that miR-107 combined with miR-1246 for diagnosis of early liver cancer metastasis is superior to alpha fetal protein (AFP), and has good sensitivity and specificity, and the miR-107 and miR-1246 combined with AFP diagnosis is more excellent. As to metastasis diagnosis of low alpha fetal protein secretion liver cancer (AFP is smaller than 200), the miR-1246 is superior to the APF, the miR-107 combined with miR-1246 diagnosis is much superior to the APF, and the miR-107 and miR-1246 combined with AFP are more excellent. On the basis, a primer, a kit and a detection method for detecting the miR-107 and the miR-1246 are developed, and the serum microRNA has a good development prospect and clinical application value. A sequence of the primer is shown in SEQ ID NO.3 and 4, and the kit is formed by a specific amplification primer and a required reagent for PCR amplification.

The invention discloses an early warning method for liver cancer, a detection kit for early warning and a detection method, and belongs to the technical field of biology. The early warning method comprises the following steps: detecting DNA methylation levels of RASSF1A, ELF, p16 and GSTP1 genes in a peripheral blood sample through a PCR method, calculating a risk value of suffering from liver cancer, and carrying out early warning according to a calculation result. The calculation formula is as follows: Y is equal to 1.208163-0.00653*Ct(RASSF1A)-0.00751*Ct(ELF)-0.00555tCT(p16)-0.00457*Ct(GSTP1), wherein when Y is larger than or equal to 0.3177, the risk is judged to be high, and when Y is smaller than 0.3177, and the risk is judged to be low. The multi-gene methylation joint detection kitfor early warning of liver cancer comprises a DNA methylation detection reagent for specifically detecting the RASSF1A, ELF, p16 and GSTP1 genes in the peripheral blood sample, an endogenous gene andan endogenous gene detection reagent. The high-risk early warning result and the clinical diagnosis result are high in conformity, good application prospects are achieved for diagnosis of early livercancer, the survival rate of liver cancer patients is increased, and the cure rate of liver cancer patients is increased.

The invention discloses an ultra-early liver cancer related screening and evaluating product based on a saliva specific glycoprotein sugar chain structure and application. Aiming at a saliva sample, aproduct for screening, early diagnosis, risk assessment, drug screening and/or curative effect assessment of the ultra-early liver cancer is provided, whether the saliva sample contains any one or any combination of specific 26 N-sugar chains or not is detected, and whether a saliva sample main body is an ultra-early liver cancer patient (not a liver cirrhosis patient) or not can be judged. Correspondingly, lectin playing a role in specific binding recognition is MAL-I and can be independently used as a reagent for recognizing a saliva specific glycoprotein sugar chain structure to be used for preparing related medical products.

The invention relates to a construction method of a liver cancer early screening model, a detection device and a computer readable medium. The lengths of WGS cfDNA read segments of 170 contrast groups and 192 liver cancer patients are counted, and the number of total fragments (40-300 bp), the number of short fragments (40-80 bp) and the number of super-long fragments (200-300 bp) are different between the number of total fragments (40-300 bp) and the number of short fragments (40-80 bp). Meanwhile, the number of fragments with different lengths is counted through long and short arms of chromosomes, and the two groups also have significant differences. According to the invention, a diagnosis model of the relationship between DNA fragment size sheet distribution and terminal sequence proportion and liver cancer is provided for the first time based on plasma cfDNA high-throughput low-depth sequencing, and the model not only can diagnose early liver cancer, but also can distinguish liver cirrhosis, and has the advantages of noninvasive detection, low throughput, and high detection specificity and sensitivity.

The invention discloses an application of a specific lectin combination in construction of a test tool for identifying ultra-early liver cancer based on a saliva glycoprotein sugar chain, wherein thespecific lectin combination is selected from three kinds of lectin of LTL, STL and MAL-I; compared with a liver cirrhosis sample, an ultra-early liver cancer sample has the advantages that LTL and MAL-I are significantly up-regulated, and STL is significantly down-regulated. Besides, an accurate test model is constructed, and a user can calculate the following detection values according to a lectin test result; if the detection value is greater than or equal to 0.4931, it is indicated that the main body to which the saliva sample belongs is an ultra-early liver cancer patient (UE-HCC), otherwise, it is indicated that the main body to which the saliva sample belongs is a liver cirrhosis patient (HC).

The invention discloses a DNA (deoxyribonucleic acid) methylation biomarker or a DNA methylation biomarker combination for early liver cancer detection, which comprises at least one of the following methylation markers: cg2088488887, cg06437004, cg10483825, cg18233405, cg18766755, cg21769702, cg27134730, cg01578265, cg18842353 and cg06613738. The invention discloses ten specific methylation markers related to occurrence of liver cancer, and the specific methylation markers can be used for remarkably improving the detection rate of early liver cancer. After the methylation marker is further combined with age and gender information, the predicted AUC value of a trained model can reach 0.917 when the model is used for distinguishing benign liver diseases (hepatitis and cirrhosis) and early liver cancer, and the model is suitable for large-scale popularization and application due to noninvasiveness of plasma detection.